![\"\"\/](\"https:\/\/www.newsbeep.com\/us-pa\/wp-content\/uploads\/2026\/02\/shutterstock_2383470841-430x241.jpg\")
<\/p>\n <\/p>\n
J&J\u2019s Pennsylvania expansion falls in line with the wider industry trend towards onshoring drug manufacturing to the US. Credit: Skorzewiak\/Shutterstock.com.<\/p>\n
Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump administration looks to onshore drug production to the US amid growing global competition.<\/p>\n Once operational, the Montgomery County-based, next-generation production site will create more than 500 skilled biomanufacturing roles. The facility\u2019s development will also open up 4,000 construction positions. The Pennsylvania facility will be J&J\u2019s eleventh site within the state, which is already home to manufacturing, distribution, research and office-based sites.<\/p>\n \n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n While J&J did not share further details on the construction timeline for the site or what it will be built to produce, the company currently has one cell therapy, Carvykti (ciltacabtagene autoleucel), on the market, which became a blockbuster seller for J&J in FY2025 after bringing in $1.9bn in global sales. GlobalData, parent company of Pharmaceutical Technology, currently forecasts that Carvykti will generate sales of $7.8bn in 2031.<\/p>\n The Pennsylvania-based facility is one of four US expansion initiatives J&J has announced in recent months \u2013 all of which fall under its $55bn initiative<\/a> to expand its manufacturing presence on home soil. Under this scheme, the company has begun construction on a $2bn biologics production facility<\/a> in Wilson, North Carolina.<\/p>\n Around the time J&J\u00a0agreed to\u00a0a\u00a0Most\u00a0Favored\u00a0Nation (MFN)\u00a0deal<\/a>\u00a0with the White House\u00a0to avoid\u00a0100% tariffs on its branded imports<\/a>, the company also\u00a0noted that it would\u00a0construct\u00a0a drug product manufacturing site in North Carolina \u2013 though no further details\u00a0on this build\u00a0were shared.\u00a0<\/p>\n J&J\u2019s moves to onshore its manufacturing to the US follow a wider trend observed across the pharma industry<\/a>, as companies look to align their activities with the Trump administration\u2019s goals. As US pharma manufacturing efforts continue, industry experts note<\/a> that newer biotech hubs like North Carolina and Virginia will gain prevalence.<\/p>\n Cell and gene therapies polarise pharma<\/p>\n While some companies like J&J double down on their cell therapy operations, this approach is not unanimous across pharma and biotech.<\/p>\n For example, Takeda chose to step away from cell therapy<\/a> to focus its attention on small molecules, biologics and antibody-drug conjugates (ADCs) back in October 2025. In the same month, Novo Nordisk and Galapagos<\/a> also shuttered their units focused on the modality.<\/p>\n Meanwhile, companies like Eli Lilly are leaning into the modality, as the pharma giant has already signed two blockbuster deals involving this drug class in 2026 \u2013 including a $1.1bn gene therapy-focused deal with Seamless Therapeutics<\/a> and an in vivo CAR-T deal worth up to $2.4bn with Orna Therapeutics<\/a>.<\/p>\n Bristol Myers Squibb (BMS), which already has two approved CAR-T therapies on the market, has also placed further emphasis on the modality through its $1.5bn buyout of Orbital Therapeutics<\/a>.<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-pa\/wp-content\/uploads\/2026\/02\/Cytiva-PT-image-1024x87.png\")
<\/a><\/p>\n![\"\"\/](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\"){kind=logo}
Discover B2B Marketing That Performs <\/p>\n
\n\t\t\t\t\t\t\tFind out more <\/a><\/p>\n
![\"Email](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\")
<\/p>\n